AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 587 businesses audited.
Merus has 8.8 points less BS than the average for Medical Devices, Pharma & Biotech.
Medical Devices, Pharma & Biotech BS: Merus (merus.nl)
Merus is a high-substance biotech entity currently undergoing a ‘zombie site’ transition following its acquisition by Genmab. While its technical claims are granular and likely legitimate, the presence of consumer-style review schemas and the abandonment of its own pipeline tracking are significant BS indicators for an industry where precision and transparency are paramount.
Remove the review_count schema and any star-rating artifacts immediately to eliminate trust theatre signals. Update the homepage H1 and meta-description to reflect the Genmab acquisition to ensure semantic coherence. Replace the ‘Scientific Publications’ button with direct, numbered citations and outbound DOI links to clinical results. Add a ‘Leadership’ section with named experts and linked LinkedIn profiles or ORCID IDs to close the authority gap.
While the homepage and pipeline page are critically insufficient (under 400 characters), the About and Technology pages provide high information density. Headings like ‘Closing in on Cancer’ and ‘Every Day’ are 100% fluff, but the body text compensates with specific technical nouns such as ‘petosemtamab,’ ‘EGFR,’ ‘LGR5,’ and ‘Phase 3 registrational trials.’ The substance ratio is high once the user navigates past the hero sections.
Hydration, modals, and JS dependent content erase entire sections of your page before AI can read them. Audit your AI visible surface to see what survives a script free crawl.
The homepage acts as a high-level signal for ‘Closing in on Cancer,’ which is substantiated by the sub-pages’ deep dives into antibody engineering. However, a significant drift occurs on the Pipeline page, where the company reveals it is ‘now part of Genmab,’ a transition not mentioned in the homepage H1 or hero text. This creates a disconnect between the brand’s independent ‘mission’ and its current corporate reality as a subsidiary.
Stop the ROI leak caused by technical debt and strategic misalignment. Conduct an Independent Strategic Diagnosis for 1 Euro to identify high impact issues across all audit categories.
The site exhibits clear Trust Theatre patterns with review_count values of 2 and 3 appearing in the schema data across multiple pages despite having 0 proof_links_count. Displaying ‘reviews’ for a clinical-stage biotech firm is a common CMS artifact that functions as BS, as medical research outcomes are not measured via consumer star ratings. Bold claims regarding ‘encouraging single agent clinical activity’ lack direct, linked citations to ClinicalTrials.gov or peer-reviewed journals within the crawled text.
The ratio of evidence is respectable, with 8+ specific technical proof points identified across the sub-pages (e.g., target combinations, specific cancer indications, and trial phases). However, the absolute lack of outbound proof links (0 counted) forces the user to take these technical claims at face value, which is a significant proof-path deficiency. The ‘View Publications’ CTA is a signal of substance that requires external navigation to verify.
To review a full competitive diagnostic applied to an enterprise level technical SEO agency, including a direct comparison against Dejan, examine the complete executive audit. View the iPullRank Executive SEO Strategy Dashboard for a practical example of how perception gaps, value prop drift, and audience misalignment are surfaced in real audits.
The brand avoids most commodity traps through its proprietary ‘Multiclonics,’ ‘Biclonics,’ and ‘Triclonics’ terminology, which are unique to their intellectual property. Industry cliches like ‘mission to close in on cancer’ and ‘passion to help patients’ are present but secondary to the technical value proposition. The template language is standard (About Us, Pipeline, Technology) but contains mostly unique, rather than boilerplate, body content.
Authority is primarily established through technical jargon and trial references rather than named human experts. The data reveals a lack of specific leadership or scientific board names (Person schema is missing), which creates an ‘anonymous corporate’ profile. The technical implementation is professional with clean JSON-LD, though the reliance on external Genmab links for current data indicates a loss of local site authority.
The marketing tone ‘Closing in on Cancer’ is a bold emotive claim, but it is backed by the mention of ‘Phase 3 registrational trials,’ which is the highest level of pre-market proof in this industry. The disconnect is minor, primarily existing in the gap between the ‘urgency’ claimed on the homepage and the reality of long-term clinical trial timelines. The transition to Genmab further complicates the ‘Our Pipeline’ performance claims.
Medical Devices, Pharma & Biotech BS: Merus (merus.nl)
The site strongly aligns with the Pharma & Biotech industry, specifically clinical-stage oncology. The presence of specific drug candidates like petosemtamab and detailed descriptions of bispecific antibody platforms (Multiclonics) confirms this classification.
Every retrieval failure begins with one root cause: the model cannot segment the page correctly. Read the Semantic HTML Technical Guide to learn how structural clarity prevents chunk collapse and embedding noise.
“The score of 32 is driven primarily by Trust and Proof deficiencies (Review counts vs Proof links) and the Semantic Drift caused by the Genmab acquisition disclosure being buried on a sub-page. The high technical specificity in the antibody descriptions prevents the score from reaching the 'Moderate BS' range.”